Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Activists have sharply criticised the US government’s move to exclude South Africa from receiving HIV prevention medication ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Miguel, a 63-year-old Los Angeles teacher, recently marked the 38th anniversary of his diagnosis with HIV. The doctor had told him he would be dead in a couple of years. He lived fearful that each ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

HOUSTON — With President Trump's "Big, Beautiful Bil l," making major cuts to Medicaid, health care professionals and patients are warning of the potentially deadly consequences for people living with ...

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...